India’s healthcare sector has entered a new phase of innovation with the launch of the country’s first AI-powered dialysis ecosystem in Ahmedabad, marking a major step toward smarter and more connected kidney care systems.
India’s drug safety network is getting a stronger push as the Centre has partnered with pharmacy councils in Bihar, Maharashtra, and Mizoram to improve adverse drug reaction reporting and strengthen medicine monitoring across the country.
Eli Lilly has halted its India obesity awareness campaign after facing regulatory scrutiny, putting the spotlight on how pharmaceutical companies promote obesity-related healthcare in the country. The U.S.-based drugmaker paused its campaig...
Chinese cancer drugs are bringing affordable relief to Indian patients as hospitals and pharmaceutical companies increasingly introduce lower-cost immunotherapy medicines into the country. The development is helping thousands of cancer pati...
Every Mother’s Day, the world celebrates motherhood with cards, flowers and images of glowing mothers. World portrays motherhood as a period of happiness, but for millions of mothers, this may be far from truth.
We observe World Thalassemia Day every year on May 8, drawing attention to one of the most widespread blood disorder in the planet.
JANANI Digital Health Platform has been launched by the Ministry of Health and Family Welfare. The platform aims to strengthen Maternal Care in India by creating a unified digital system for tracking care across pregnancy, childbirth, and...
Nutrition aid for TB patients, TB patients in India, and efforts to reduce tuberculosis deaths could save nearly 1.2 lakh lives every year, according to a new study that highlights the critical link between food support and tuberculosis treatme...
India’s pharma exports crossed the $31 billion mark in FY26 despite a challenging global business environment and slower demand in some international markets. The strong growth highlights the resilience of the Indian pharmaceutical indust...
In a significant development, an advisory panel of the U.S. Food and Drug Administration (FDA) has backed AstraZeneca’s prostate cancer combination therapy in a key vote, strengthening its chances of regulatory approval and offering new hop...
.jpg)
.jpg)
, CDSCO.jpg)